Aptorum Group Limited
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ian Huen
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17 Hanover Square London GL United Kingdom W1S 1BN
- IPO Date
- Dec 18, 2018
- CIK
- 0001734005
- Website
- aptorumgroup.com
- Similar Companies
- Business
- Aptorum Group Limited (Nasdaq: APM) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic assets targeting unmet medical needs in oncology, including orphan indications, infectious diseases, neurology, gastroenterology, and other areas. The company operates through Therapeutics and Non-Therapeutics segments, with its Therapeutics division advancing repurposed small-molecule candidates such as SACT-1 in Phase 1 trials for neuroblastoma and other cancers, SACT-COV19 for coronavirus disease, ALS-4 in Phase 1 for bacterial infections including methicillin-resistant Staphylococcus aureus and Mycobacterium tuberculosis, and ALS-1 for influenza A virus infections; additional pipeline efforts encompass Smart-Act, Acticule, RPIDD, Nativus, and Claves series platforms for systematic drug screening, microbiome-based metabolic disease treatments, and projects in women's health. The Non-Therapeutics segment includes molecular-based rapid pathogen identification diagnostics (RPIDD), AML Clinic operations, and sales of natural supplements; the company also maintains a CLIA-licensed, CAP-accredited clinical laboratory through recent strategic developments. Founded in 2010 by Ian Huen and headquartered at 17 Hanover Square, London W1S 1BN, United Kingdom, Aptorum Group conducts operations primarily from its principal office in Asia to leverage regional research resources and collaborations with leading academic institutions, holding exclusive licenses to 11 technologies across neurology, infectious diseases, gastroenterology, oncology, surgical robotics, and natural health; it serves global markets with a focus on complex-biology indications. In July 2025, Aptorum Group entered a definitive all-stock merger agreement with DiamiR Biosciences, under which DiamiR will become a wholly-owned subsidiary, combining Aptorum's drug development expertise with DiamiR's blood-based biomarker tests for brain health, neurodegenerative diseases like Alzheimer's, neurodevelopmental disorders, oncology, and autoimmune conditions to enable near-term revenue from biopharma services and clinical laboratory operations; the merger, pending shareholder approval and other contingencies, aims to position the combined entity as a global life sciences leader in non-invasive diagnostics. To support merger-related expenses and working capital, the company completed a $2 million registered direct offering in October 2025 with up to $4 million additional from warrants, followed by a $3.0 million offering of 1,535,000 Class A ordinary shares at $2.00 each in late 2025, expected to close around January 3, 2026.
Aptorum Group Provides Update on DiamiR Biosciences Merger
Aptorum Group Provides Update on DiamiR Biosciences Merger
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers
Statement in Response to Silver Elephant's News Release Dated June 17, 2026
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
Andean Precious Metals Corp. (APM:CA) Q1 2026 Earnings Call Transcript
Head-To-Head Survey: Aptorum Group (NASDAQ:APM) versus Catalyst Pharmaceuticals (NASDAQ:CPRX)
Aptorum Group Limited (NASDAQ:APM) Short Interest Up 41.4% in March
Prelude Therapeutics (NASDAQ:PRLD) vs. Aptorum Group (NASDAQ:APM) Critical Review
Andean Precious Metals Q4 Earnings Call Highlights
Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript
Aptorum Group Limited (NASDAQ:APM) Sees Significant Growth in Short Interest
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease
Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 75.1%
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference
Andean Precious Metals Corp. (APM:CA) Q3 2025 Earnings Call Transcript